Clinical Trial Update: Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) [Phase 2]

View source ↗

Summary

Open-label Phase 2 study of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma (CITADEL-213); results from this trial have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Parsaclisib (parsaclisib)

Snippet

Sponsor: Incyte Biosciences Japan GK | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-01-03